Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV

Annals of Oncology

Volumn 27, Issue 2, 2016, Pages 267-274

  Lévi, Francis A ^a,b,c,d   Boige, V ^e   Hebbar, M ^f   Smith, D ^g   Lepere C ^h   Focan, C ⁱ   Karaboue A ^a,b,c   Guimbaud, R ^j   Carvalho, C ^k   Tumolo, S ^l   Innominato, P ^a,b,c,d   Ajavon, Y ^c   Truant, S ^f   Castaing, D ^b,c   De Baere, T ^e   Kunstlinger, F ^c   Bouchahda, M ^a,b,c   Afshar, M ^d   Rougier, P ^h,m   Adam, R ^a,b,c   Ducreux, M ^b,c,e   more..

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g HÔPITAL SAINT ANDRÉ   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ Clinique Saint Joseph   (Belgium)

^j CHU PURPAN   (France)

^k Medical Oncology Unit   (Portugal)

^l Santa Maria Degli Angeli Community Hospital   (Italy)

^m UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

Cetuximab; Chronotherapy; Colorectal cancer; Hepatectomy; Hepatic artery infusion; Liver metastases

Indexed keywords

CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; KRAS PROTEIN, HUMAN; PLATINUM COMPLEX; PROTEIN P21;

ABDOMINAL PAIN; ADULT; AGED; ARTERY CATHETER; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CATHETER OCCLUSION; COLORECTAL CANCER; CYTOLYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEART ARRHYTHMIA; HEPATIC ARTERY THROMBOSIS; HUMAN; LIVER FAILURE; LIVER FIBROSIS; LIVER METASTASIS; LIVER RESECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; SURVIVAL TIME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; GENETICS; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEPATECTOMY; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 84961642214     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv548     Document Type: Article

References (31)

1. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
2. Hugen N, van de Velde CJH, de Witt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol 2014; 25(3): 651-657.
3. Lévi F, Zidani R, Misset JL et al. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997; 350(9079):681-686.
4. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669.
5. Adam R, De Gramont A, Figueras J et al. of the EGOSLIM (Expert Group on OncoSurgery management of Liver Metastases) group. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. The Oncologist 2012; 17: 1225-1239.
6. Bouchahda M, Lévi F, Adam R, Rougier P. Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. Eur J Cancer 2011; 47: 2681-2690.
7. Kemeny NE, Melendez FD, Capanu M et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009; 27: 3465-3471.
8. Ducreux M, Ychou M, Laplanche A et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005; 23(22): 4881-4887.
9. Boige V, Malka D, Elias D et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008; 15: 219-226.
10. Goéré D, Deshaies I, de Baere T et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 2010; 251: 686-691.
11. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
12. Assenat E, Desseigne F, Thezenas S et al. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. The Oncologist 2011; 16: 1557-1564.
13. Masi G, Vasile E, Loupakis F et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 2011; 103: 21-30.
14. Adam R, Aloia T, Lévi F et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007; 25: 4593-4602.
15. Ye LC, Liu TS, Ren L et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liverlimited metastases. J Clin Oncol 2013; 31: 1931-1938.
16. Folprecht G, Gruenberger T et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 2014; 25: 1018-1025.
17. Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075.
18. Garufi C, Torsello A, Tumolo S et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010; 103: 1542-1547.
19. Lévi F, Karaboué A, Gorden L et al. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC):safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol 2011; 67: 339-348.
20. Bouchahda M, Adam R, Giacchetti S et al. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer 2009; 115: 4990-4999.
21. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. ESMO Guidelines Working Group Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl 3): iii1-iii9.
22. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med 2001; 20: 859-866.
23. Saridaki Z, Androulakis N, Vardakis N et al. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Br J Cancer 2012; 107: 1932-1937.
24. Petrelli F, Cabiddu M, Borgonovo K, Bami S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012; 23: 1672-1679.
25. Nielsen DL, Palshof JA, Larsen FO et al. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan ± targeted therapy. Cancer Treat Rev 2014; 40: 701-715.
26. Gill S, Dowden S, Colwell B et al. Navigating later lines of treatment for advanced colorectal cancer-optimizing targeted biological therapies to improve outcomes. Cancer Treat Rev 2014; 40: 1171-1181.
27. Grothey A, Van Cutsem E, Sobrero A et al. CORRECT Study Group Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381(9863): 303-312.
28. Mayer RJ, Van Cutsem E, Falcone A et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372: 1909-1919.
29. D'Angelica MI, Correa-Gallego C, Paty PB et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg 2015; 261: 353-360.
30. Bokemeyer C, Van Cutsem E, Rougier P et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-1475.
31. Loupakis F, Cremolini C, Masi G et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609-1618.